This page will host Events plug-in for all Clarion and trade events.

Upcoming Events

View Calendar
Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

40.24 +0.25 (+0.64%)
Streaming Delayed Price Updated: 2:42 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,095,977
Open 40.01
Bid (Size) 40.23 (3)
Ask (Size) 40.26 (10)
Prev. Close 39.99
Today's Range 39.45 - 40.62
52wk Range 28.05 - 49.62
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advanced kidney cancer. 
Via Benzinga
EXELIXIS INC (NASDAQ:EXEL) Represents an Affordable Growth Opportunity
Discover EXELIXIS (EXEL), an affordable growth stock with strong profitability, sound finances, and a compelling valuation in the biotech sector. 
Via Chartmill

Performance

YTD
+18.6%
+18.6%
1 Month
-0.8%
-0.8%
3 Month
-9.3%
-9.3%
6 Month
+4.7%
+4.7%
1 Year
+41.2%
+41.2%

More News

Read More
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Exelixis, Inc.
Via Business Wire
This Nextracker Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
17 Analysts Have This To Say About Exelixis
Via Benzinga
Peering Into Exelixis's Recent Short Interest
Via Benzinga
Top 3 Health Care Stocks You'll Regret Missing In October
Via Benzinga
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results
Via Benzinga
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
From Exelixis, Inc.
Via Business Wire
The Ultimate Biotech Stock to Buy With $50 Right Now
Via The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) Identified as a Quality Value Stock by Fundamental Screening
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Stands Out as an Affordable Growth Stock
Via Chartmill
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Via The Motley Fool
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Undervalued Stock with Strong Fundamentals
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
Exelixis Inc (NASDAQ:EXEL) Embodies the Affordable Growth Investment Strategy
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
From Exelixis, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Exelixis, Inc. - Common Stock publicly traded?
Yes, Exelixis, Inc. - Common Stock is publicly traded.
What exchange does Exelixis, Inc. - Common Stock trade on?
Exelixis, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Exelixis, Inc. - Common Stock?
The ticker symbol for Exelixis, Inc. - Common Stock is EXEL on the Nasdaq Stock Market
What is the current price of Exelixis, Inc. - Common Stock?
The current price of Exelixis, Inc. - Common Stock is 40.24
When was Exelixis, Inc. - Common Stock last traded?
The last trade of Exelixis, Inc. - Common Stock was at 10/28/25 02:42 PM ET
What is the market capitalization of Exelixis, Inc. - Common Stock?
The market capitalization of Exelixis, Inc. - Common Stock is 12.68B
How many shares of Exelixis, Inc. - Common Stock are outstanding?
Exelixis, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.